256 related articles for article (PubMed ID: 25487669)
1. Risk factors for persistent proteinuria after a 2-year combination therapy for severe childhood IgA nephropathy.
Kamei K; Nakanishi K; Ito S; Ishikura K; Hataya H; Honda M; Nozu K; Iijima K; Shima Y; Yoshikawa N;
Pediatr Nephrol; 2015 Jun; 30(6):961-7. PubMed ID: 25487669
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of a randomized controlled trial in childhood IgA nephropathy.
Kamei K; Nakanishi K; Ito S; Saito M; Sako M; Ishikura K; Hataya H; Honda M; Iijima K; Yoshikawa N;
Clin J Am Soc Nephrol; 2011 Jun; 6(6):1301-7. PubMed ID: 21493743
[TBL] [Abstract][Full Text] [Related]
3. Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy.
Shima Y; Nakanishi K; Kamei K; Togawa H; Nozu K; Tanaka R; Sasaki S; Iijima K; Yoshikawa N
Nephrol Dial Transplant; 2011 Jan; 26(1):163-9. PubMed ID: 20601366
[TBL] [Abstract][Full Text] [Related]
4. Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study).
Shima Y; Nakanishi K; Sako M; Saito-Oba M; Hamasaki Y; Hataya H; Honda M; Kamei K; Ishikura K; Ito S; Kaito H; Tanaka R; Nozu K; Nakamura H; Ohashi Y; Iijima K; Yoshikawa N;
Pediatr Nephrol; 2019 May; 34(5):837-846. PubMed ID: 30284023
[TBL] [Abstract][Full Text] [Related]
5. A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease.
Kawamura T; Joh K; Okonogi H; Koike K; Utsunomiya Y; Miyazaki Y; Matsushima M; Yoshimura M; Horikoshi S; Suzuki Y; Furusu A; Yasuda T; Shirai S; Shibata T; Endoh M; Hattori M; Katafuchi R; Hashiguchi A; Kimura K; Matsuo S; Tomino Y;
J Nephrol; 2013; 26(2):350-7. PubMed ID: 22684645
[TBL] [Abstract][Full Text] [Related]
6. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
Li X; Liu Y; Lv J; Shi S; Liu L; Chen Y; Zhang H
Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT.
Shima Y; Nakanishi K; Kaku Y; Ishikura K; Hataya H; Matsuyama T; Honda M; Sako M; Nozu K; Tanaka R; Iijima K; Yoshikawa N;
Pediatr Nephrol; 2018 Nov; 33(11):2103-2112. PubMed ID: 29987456
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Progression in IgA Nephropathy in Childhood.
Mizerska-Wasiak M; Małdyk J; Turczyn A; Cichoń-Kawa K; Rybi-Szumińska A; Wasilewska A; Bieniaś B; Zajączkowska M; Miklaszewska M; Pietrzyk J; Demkow U; Roszkowska-Blaim M; Pańczyk-Tomaszewska M
Adv Exp Med Biol; 2017; 955():65-73. PubMed ID: 27718216
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of corticosteroids in immunoglobulin A nephropathy with less than 25% crescents.
Chen J; Xu H; Peng Z; Lin L; Li C; Zhu X; Liu S
Clin Exp Nephrol; 2020 Jan; 24(1):73-81. PubMed ID: 31605314
[TBL] [Abstract][Full Text] [Related]
10. The impact of sex in primary glomerulonephritis.
Cattran DC; Reich HN; Beanlands HJ; Miller JA; Scholey JW; Troyanov S;
Nephrol Dial Transplant; 2008 Jul; 23(7):2247-53. PubMed ID: 18182409
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathological analysis of IgA nephropathy with crescentic formation in childhood].
Yao Y; Liu JC; Xiao HJ; Huang JP; Yang JY
Zhonghua Er Ke Za Zhi; 2004 Jun; 42(6):412-6. PubMed ID: 15265422
[TBL] [Abstract][Full Text] [Related]
12. Effect and therapeutic mechanisms of tonsillectomy for childhood IgA nephropathy.
Nishi H; Sugimoto K; Fujita S; Miyazaki K; Miyazawa T; Sakata N; Okada M; Takemura T
Nephrology (Carlton); 2012 Sep; 17(7):658-64. PubMed ID: 22616843
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study.
Yoshikawa N; Nakanishi K; Ishikura K; Hataya H; Iijima K; Honda M;
Pediatr Nephrol; 2008 May; 23(5):757-63. PubMed ID: 18224343
[TBL] [Abstract][Full Text] [Related]
14. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Cheng G; Liu D; Margetts P; Liu L; Zhao Z; Liu Z; Tang L; Fang Y; Li H; Guo Y; Chen F; Liu F
Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
[TBL] [Abstract][Full Text] [Related]
15. Prognostic indicators and treatment of childhood IgA nephropathy.
Hogg RJ
Contrib Nephrol; 1995; 111():194-9; discussion 199-200. PubMed ID: 7758342
[No Abstract] [Full Text] [Related]
16. Significance of tonsillectomy combined with steroid pulse therapy for IgA nephropathy with mild proteinuria.
Komatsu H; Sato Y; Miyamoto T; Tamura M; Nakata T; Tomo T; Nishino T; Miyazaki M; Fujimoto S
Clin Exp Nephrol; 2016 Feb; 20(1):94-102. PubMed ID: 26123429
[TBL] [Abstract][Full Text] [Related]
17. Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy.
Yagi K; Okada M; Yanagida H; Kuwajima H; Ikeda M; Sugimoto K; Takemura T
Clin Exp Nephrol; 2003 Dec; 7(4):270-4. PubMed ID: 14712355
[TBL] [Abstract][Full Text] [Related]
18. Epidemiological survey and clinical investigation of pediatric IgA nephropathy.
Shibano T; Takagi N; Maekawa K; Mae H; Hattori M; Takeshima Y; Tanizawa T
Clin Exp Nephrol; 2016 Feb; 20(1):111-7. PubMed ID: 26041644
[TBL] [Abstract][Full Text] [Related]
19. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation.
Shen XH; Liang SS; Chen HM; Le WB; Jiang S; Zeng CH; Zhou ML; Zhang HT; Liu ZH
J Nephrol; 2015 Aug; 28(4):441-9. PubMed ID: 25585823
[TBL] [Abstract][Full Text] [Related]
20. Validation of some pathophysiological mechanisms of the CKD progression theory and outcome prediction in IgA nephropathy.
Bazzi C; Rizza V; Casellato D; Stivali G; Rachele G; Napodano P; Olivieri G; Gallieni M; D'Amico G
J Nephrol; 2012; 25(5):810-8. PubMed ID: 22252844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
